CNTX
Context Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.37
−3.99%Sep 9, 2026, 11:30 UTC
Context Therapeutics announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody, for solid tumors.
Source:Jun 15, 2026, 15:10 UTC
Context Therapeutics released interim Phase 1 data for CTIM-76, a CLDN6 x CD3 T-cell engaging bispecific antibody, in patients with advanced platinum-resistant ovarian cancer.
Source: